Find in Library

More and more paclitaxel-coated devices are used for the treatment of lower-extremity peripheral artery disease (LE-PAD). A recent meta-analysis containing 28 randomized controlled trials (RCTs) reported an increased risk of all-cause mortality in the paclitaxel-coated devices'group. However, more studies showed this result was controversial. In this article, we further analyze the meta-analysis report and 4 other RCTs with long-term outcomes, and also disscuss the most recent new evidence concerning paclitaxel-coated devices and mortality. We then provide a perspective on how to use paclitaxel-coated devices for LE-PAD and make patient-centered decision. In a word, due to the lack of long-term RCTs data and large sample real-world long-term data, it is quite immature to link the paclitaxel-coated devices with all-cause mortality. In future, long-term treatment evidence of RCTs and large sample real-world researches is needed.